Navigation Links
Metamark Genetics Signs Collaboration Agreement on Novel Therapeutic Targets with Janssen Biotech
Date:12/19/2011

CAMBRIDGE, Mass., Dec. 19, 2011 /PRNewswire/ -- Metamark Genetics, Inc. announced today that it has entered into a research, collaboration, and license agreement with Janssen Biotech, Inc.  The agreement is based on Metamark's discovery platform for the identification and characterization of specific proprietary cancer targets demonstrated to play a causal role in promoting tumor progression and spread (Prognosis Determinants™). The collaboration will focus on the evaluation and validation of several of Metamark's Prognosis Determinants. Upon selection of the targets, Janssen Biotech will receive a limited exclusive license under Metamark's intellectual property and know-how and will thereafter be responsible for the discovery, development, and commercialization of therapeutic inhibitors targeting the specific Prognosis Determinants.

 "We are delighted to enter into this important alliance with Janssen Biotech," said Eric Devroe, Ph.D., Vice President of Business & Strategy Development at Metamark. "This collaboration and license agreement reflects the value of Metamark's innovative approach to identifying genes and proteins that drive aggressive behavior of tumors – both in the development of prognostic assays as well as in supporting the discovery and development of novel targeted therapeutics."

Metamark will receive an initial upfront payment from Janssen Biotech as well as near-term milestone payments following initial target validation. Under the terms of the agreement, Metamark may be eligible to receive up to $365 million in milestone payments across multiple targets, based upon the achievement of specified development, regulatory, and commercialization goals. In addition, Metamark will be entitled to royalties on worldwide net sales of therapeutics and any associated companion diagnostics upon commercialization.

Commenting on the agreement, Metamark President and CEO, Mark R. Straley, stated, "Our ulti
'/>"/>

SOURCE Metamark Genetics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Metamark Genetics, Inc. Announces New Chief Scientific Officer
2. Metamark Genetics, Inc. Announces New Chief Executive Officer
3. Metamark and HistoRx Announce Licensing Agreement for AQUA® Technology
4. Interleukin Genetics Licenses its PST(R) Genetic Test to OralDNA Labs
5. deCODE genetics to Webcast Presentation at Thomas Weisel Partners Healthcare Conference 2008
6. Interleukin Genetics and Alticor Agree on Expansion of Distribution Channels for Genetic Tests
7. Expression Genetics EGEN-001 Named One of 10 Most Promising Oncology Products by Windhover
8. Exosome Diagnostics Appoints Johan Skog, Ph.D., as Director of Genetics Research
9. MedImmune Licenses Reverse Genetics Technology to Hungarys Omninvest for Use in Influenza Vaccine Development and Production
10. deCODE genetics Announces Webcast of Conference Call to Discuss Third Quarter 2008 Financial Results
11. Interleukin Genetics to Present New Findings at the 11th Cardiovascular Genomics and Atherosclerosis Symposium
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/25/2014)... 23, 2014 ViaDerma, Inc ... company devoted to bringing new products to market, ... , ViaDerma has developed an innovative, patent-pending dual ... mass transfer of pharmaceutical active ingredients to penetrate ... immediate localized therapy. The transdermal delivery method also ...
(Date:10/25/2014)... Va. (PRWEB) October 24, 2014 ... the nation’s leading nonprofit authority on the ... healthcare information exchange, announces its appointment of four ... Workgroup. The workgroup leaders include:, , ... ,     Erik Pupo, Specialist Leader, Deloitte Consulting ...
(Date:10/25/2014)... A new way to produce engineered skin ... skin grafting technologies, it also speeds up the healing ... in the October issue of STEM CELLS Translational Medicine, ... that result from severe burns and chronic wounds. , ... elements. These wounds heal by contraction, with epithelization (the ...
(Date:10/25/2014)... 2014  RegeneRx Biopharmaceuticals, Inc. (OTCBB: RGRX) ("the Company" ... Fourth International Symposium on Thymosins in Health and Disease ... "When thymosin beta 4 (TB4) linked with rhodamine ... cavity in a rodent model of stroke, it was ... parenchyma (the functional tissue of the brain).   The leakage ...
Breaking Biology Technology:ViaDerma, Inc. Announces Plans to Pursue Out-Licensing Partnerships in 2015 2ViaDerma, Inc. Announces Plans to Pursue Out-Licensing Partnerships in 2015 3WEDI Appoints Four New Security and Privacy Workgroup Co-chairs 2New engineering method shows promise for faster healing, more cosmetically appealing skin grafts 2New engineering method shows promise for faster healing, more cosmetically appealing skin grafts 3Researchers Report Thymosin Beta 4 Crosses Blood-Brain Barrier In Animal Stroke Model 2
... Sept. 7 On Thursday, October,18, 2007, Wyeth (NYSE: ... 2007,third quarter. The Company will hold a one-hour conference ... October 18, 2006. Interested,investors and others may listen to ... Internet webcast, which may be accessed by visiting our ...
... Richard Gabriel, Chief,Executive Officer of DNAPrint Genomics, ... be featured in an exclusive interview with, http://www.wallst.net ... September 10 at 11,a.m. EDT. The interview will ... p.m.,EDT on September 10. The interview will ...
... York City 5:30-7:30 p.m. (ET), SAN DIEGO, Sept. ... focused on developing products for,minimally disruptive surgical treatments for ... reception for institutional investors and,analysts at the Waldorf=Astoria Hotel ... 5:30 p.m. to 7:30 p.m. ET. The reception ...
Cached Biology Technology:WallSt.net (www.wallst.net) Announces Upcoming Interview With CEO of DNAPrint Genomics 2NuVasive to Host Investor Reception on September 11, 2007 2NuVasive to Host Investor Reception on September 11, 2007 3NuVasive to Host Investor Reception on September 11, 2007 4
(Date:10/22/2014)... discovery by Northwestern Medicine® scientists helps explain how bipolar ... to new drug therapies to treat the mental illness. ... -- the same method recognized with the 2014 ... into brain tissue from mice with bipolar-like behaviors. In ... discovered tiny "nanodomain" structures with concentrated levels of ANK3 ...
(Date:10/18/2014)... 2014 Psychological stress and stress-related psychiatric disorders are ... but the molecular mechanisms underlying this relation ... to the development of targeted preventive strategies ... devastating diseases. This work is presented at ... Berlin., Now an international group of researchers ...
(Date:10/17/2014)... Copenhagen have shown for the first time how bacteria ... patients, giving them the opportunity to get tremendous insights ... The study also discovered the bacterial growth in chronic ... or slowed down by the immune cells. The researchers ... helped "suffocate" the bacteria, forcing the bacteria to switch ...
Breaking Biology News(10 mins):Bipolar disorder discovery at the nano level 2Researchers find why depression and aging linked to increased disease risk 2Scientists opens black box on bacterial growth in cystic fibrosis lung infection 2
... biochemists have developed an approach that allows them to ... in a protein. The scientists were then able ... protein based on structural information, a novel outcome that ... Academy of Sciences. , Professor of biochemistry John Markley, ...
... are so crucial to survival that the brains of all ... long enough to allow the animal to eat, drink -- ... from researchers at the University of Chicago, published early online ... that by activating "OFF" cells and shutting down "ON" cells ...
... classic "Flowers for Algernon," but adds a happy ending, UCLA ... reverse the attention deficits linked to the leading genetic cause ... Biology reports the findings, which were studied in mice bred ... , The results proved so hopeful, that the Food and ...
Cached Biology News:Scientist uses form to explain function of key building blocks of life 2Brainstem blocks pain to protect key behaviors 2Brainstem blocks pain to protect key behaviors 3Recreating 'Flowers for Algernon' with a happy ending 2Recreating 'Flowers for Algernon' with a happy ending 3
Mouse monoclonal [1241] to Parainfluenza Virus type 2...
Mouse monoclonal [0.N.509] to PCTAIRE2 ( Abpromise for all tested applications). entrezGeneID: 5128 SwissProtID: Q00537...
Parathyroid Hormone Receptor 2 [PTHR2]...
... the caudal-related homeobox family, is an intestine-specific ... differentiation in intestinal epithelial cells. It plays ... the phenotype of differentiated villus enterocytes as ... phenotype. Clone CDX2-88 reacts with a conserved ...
Biology Products: